182 results on '"Finazzi, Guido"'
Search Results
2. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
3. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.
4. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
5. Molecular characterization of Yersinia enterocolitica strains to evaluate virulence associated genes.
6. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
7. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
8. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study
9. Evaluation of the Virulence Potential of Listeria monocytogenes through the Characterization of the Truncated Forms of Internalin A.
10. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
11. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
12. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
13. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
14. Myeloproliferative neoplasms and thrombosis
15. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera
16. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
17. The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera
18. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
19. Front-line therapy in polycythemia vera and essential thrombocythemia
20. Newly Designed Primers for the Sequencing of the inlA Gene of Lineage I and II Listeria monocytogenes Isolates.
21. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
22. Thrombosis in primary myelofibrosis: incidence and risk factors
23. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
24. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
25. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
26. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera
27. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
28. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
29. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia
30. Masked polycythemia vera diagnosed according to WHO and BCSH classification
31. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia
32. Masked polycythemia Vera (mPV): Results of an international study
33. Is SARS-CoV-2 a Concern for Food Safety? A Very Low Prevalence from a Food Survey during the COVID-19 Pandemic in Northern Italy.
34. Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia
35. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
36. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
37. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
38. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
39. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
40. Current Treatment Approaches of Polycythemia Vera
41. The epidemiology of the antiphospholipid syndrome: Who is at risk?
42. Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients.
43. Evidence-based management of polycythemia vera
44. Idiopathic erythrocytosis and other non-clonal polycythemias
45. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
46. ASXL1 mutations in primary and secondary myelofibrosis
47. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
48. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
49. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
50. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 2: Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.